Amarin Corp Plc (AMRN)

[alternatepatel]

Williams,

no offence reg. <waste of time>, its just my opinion. You said..

1. '..If BP did file two weeks before MAPP 5021 with the intent to delay Vascepa NCE Amarin has a lawsuit. ..'

Who said MAPP 5021 means NCE for Vascepa? Can you show me official writing that says MAPP 5021 is being introduced to ease out decisions on NCEs? If not, then probably CP has nothing to do with delay in Vascepa NCE decision (which was already delayed by almost a year even before CP was filed!)

2. You initially suspected (heavily) that GSK was all after this CP. But GSK's reply is totally opposite. Totally. Now you are guessing AZN is after CP. I don't know who really is behind the scenes (if there is one) but one thing for sure, this CP has nothing to do with Vascepa NCE. The CP is not at all aimed at listing EEPA and EDHA as active in the OB.

3. All other info you posted depicts BPs delaying generic entry using CPs. Though CP can be used for any ill purpose, i do not agree with you about this CP delaying Vascepa NCE.

with all due respect.